Eye on Pharma: Eylea Biosimilar Suspension; New FDA Labeling Guidance; Alvotech Reinspection
Samsung Bioepis suspends development for its biosimilar referencing Eylea (aflibercept); the FDA updates its labeling recommendations for interchangeable biosimilars; Alvotech receives a Form 483 after the FDA reinspected its Iceland-based manufacturing facility.
Source: centerforbiosimilars.com